Table 2 Synthetic retinoids in terminated or active (in bold) clinical trials and approved for commercialization.
From: Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine
Drug | Receptor activity | Indication | Clinical trial |
|---|---|---|---|
Tamibarotene (or Am80) | RARα agonist | Crohn’s disease | Phase II (NCT00417391) |
| Â | Â | APL | Phase II (NCT00520208) |
| Â | Â | Advanced nonsmall cell lung cancer | Phase I (NCT01337154) |
| Â | Â | AML or myelodysplastic syndrome | Phase II (NCT02807558) |
Palovarotene | RARγ agonist | Eye dry disease | Phase I (CTP300302) |
| Â | Â | Fibrodysplasia ossificans progressive | Phase III (NCT03312634) |
| Â | Â | Multiple osteochondromas | Phase II (NCT03442985) |
Trifarotene (cream) | RARγ agonist | Moderate facial and truncal acne vulgaris | Phase III (NCT03915860) |
| Â | Â | Autosomal recessive ichthyosis with lamellar scale | Phase II (NCT03738800) |
| Â | Â | Early cutaneous T-cell lymphoma | Phase I (NCT01804335) |
Bexarotene (capsules) | Pan agonist | Refractory cutaneous T-cell lymphoma | Approved by FDA since 1999 |
Tazarotene (gel or cream) | Pan agonist | Hand–foot skin reactions | Phase II (NCT04071756) |
| Â | Â | Facial acne vulgaris | Approved by FDA since 1997 |
| Â | Â | Plaque psoriasis | Approved by FDA since 1997 |
Adapalene (solution, cream, and lotion) | Pan agonist | Acne | Approved by FDA since 1996 |
AGN194204 | RXR agonist | Prostate cancer | Phase II (NCT01540071) |
UAB30/9-cis-UAB30 | RXR agonist | Nonmelanoma skin cancer | Phase I/II (NCT03327064) |
Fenretinide (oral powder and intravenous liquid emulsion) | Atypical retinoid | Peripheral T-cell lymphoma | Phase II (NCT02495415) |
| Â | Â | Solid tumor (relapsed malignancies) | Phase I (NCT01553071) |
| Â | Â | High risk cancer | Phase III (NCT01479192) |
| Â | Â | Prevention of bladder cancer | Phase III (NCT00004154) |
| Â | Â | Cervical neoplasia | Phase III (NCT00003075) |
| Â | Â | Schizophrenia | Phase III (NCT00534898) |
| Â | Â | Breast cancer | Phase III (NCT01357772) |
